Gaucher Disease in Bone: From Pathophysiology to Practice by Hughes, D et al.
REVIEW
GAUCHER DISEASE IN BONE: FROM PATHOPHYSIOLOGY
TO PRACTICE
Derralynn Hughes,1 Peter Mikosch,2 Nadia Belmatoug,3 Francesca Carubbi,4 TimothyM Cox,5 Ozlem Goker‐Alpan,6
Andreas Kindmark,7 PramodK Mistry,8 Ludger Poll,9 Neal Weinreb,10 and Patrick Deegan11
1Royal Free London NHS Foundation Trust and University College London, UK
2Department of Internal Medicine 2, Landesklinikum Mistelbach, Austria, and Medical University Vienna, Externe Lehre, Vienna, Austria
3Referral Center for Lysosomal Diseases, Department of Internal Medicine, University Hospital Paris Nord Val de Seine, Assistance Publique‐Hôpitaux
de Paris, Clichy, France
4Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, NOCSAE Hospital, AOU Modena, Italy
5Department of Medicine, University of Cambridge, Cambridge, UK
6Lysosomal Disorders Research and Treatment Unit, Fairfax, VA, USA
7Department of Endocrinology and Diabetology, Uppsala University Hospital, Uppsala, Sweden
8Department of Internal Medicine (Digestive Diseases), Yale University School of Medicine, New Haven, CT, USA
9Practice of Radiology and Nuclear Medicine Duisburg‐Moers, Heinrich‐Heine University Düsseldorf, Duisburg, Germany
10Departments of Human Genetics and Medicine (Hematology), Miller School of Medicine, University of Miami, FL, USA
11Lysosomal Disorders Unit, Addenbrooke’s Hospital, Cambridge, UK
ABSTRACT
Gaucher disease (GD) is a rare, genetic lysosomal disorder leading to lipid accumulation and dysfunction in multiple organs.
Involvement of the skeleton is one of the most prevalent aspects of GD and a major cause of pain, disability, and reduced quality
of life. Uniform recommendations for contemporary evaluation and management are needed. To develop practical clinical
recommendations, an international group of experienced physicians conducted a comprehensive review of 20 years’ of the
literature, deﬁning terms according to pathophysiological understanding and pointing out best practice and unmet needs related
to the skeletal features of this disorder. Abnormalities of bone modeling, reduced bone density, bone infarction, and plasma cell
dyscrasias accompany the displacement of healthy adipocytes in adult marrow. Exposure to excess bioactive glycosphingolipids
appears to aﬀect hematopoiesis and the balance of osteoblast and osteoclast numbers and activity. Imbalance between bone
formation and breakdown induces disordered trabecular and cortical bone modeling, cortical bone thinning, fragility fractures,
and osteolytic lesions. Regular assessment of bone mineral density, marrow inﬁltration, the axial skeleton and searching for
potential malignancy are recommended. MRI is valuable for monitoring skeletal involvement: It provides semiquantitative
assessment of marrow inﬁltration and the degree of bone infarction. When MRI is not available, monitoring of painful acute bone
crises and osteonecrosis by plain X‐ray has limited value. In adult patients, we recommend DXA of the lumbar spine and left and
right hips, with careful protocols designed to exclude focal disease; serial follow‐up should be done using the same standardized
instrument. Skeletal health may be improved by common measures, including adequate calcium and vitamin D and management
of pain and orthopedic complications. Prompt initiation of speciﬁc therapy for GD is crucial to optimizing outcomes and
preventing irreversible skeletal complications. Investing in safe, clinically useful, and better predictive methods for determining
bone integrity and fracture risk remains a need. © 2019 The Authors. Journal of Bone and Mineral Research Published by Wiley
Periodicals Inc.
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Introduction
Pathophysiology, diagnosis, and treatment of Gaucher
disease
Gaucher disease (GD) is a lysosomal disorder leading to lipidaccumulation. The lysosome is an intracellular organelle
that degrades and recycles biological macromolecules derived
either endogenously, from digestion of cellular components
(autophagy), or from the breakdown of material incorporated
from outside the cell by phagocytosis. Sphingolipids, amphi-
philic compounds with a lipophilic moiety based on the amino‐
alcohol sphingosine, are found in all plasma membranes. They
mediate diverse cellular functions and serve as speciﬁc
receptors and cell‐recognition markers. Ultimately, they are
delivered to the lysosomal compartment during the course of
membrane turnover in endocytosis and phagocytosis. Gluco-
sylceramide is the sphingolipid degraded by the acid hydrolase
glucocerebrosidase (also named acid β‐glucosidase), whose
role it is to cleave the ﬁnal sugar, a glucose moiety, from the
ceramide component. Glucosylsphingosine, the deacylated
form of the glucosylceramide, is water‐soluble and hence
freely diﬀusible and may be relevant in the pathogenesis of GD.
About one in 5000 live‐born infants has a lysosomal disorder,
with GD and Fabry disease (both sphingolipidoses) probably
the most frequent. GD is caused by the inherited deﬁciency of
the acid hydrolase glucocerebrosidase causing an accumula-
tion of its substrate glucosylceramide. Glucosylceramide
accumulates mainly in the macrophages, transforming them
into Gaucher cells.
GD was once regarded as the most frequent lysosomal
disease; however, Fabry disease has ultimately proved more
frequent. The birth incidence is calculated to be approximately
1/100,000, depending on the ethnic composition of the
population. The inheritance pattern is autosomal recessive.
More than 250 mutations responsible for the enzymatic
deﬁciency have been identiﬁed in the human glucocerebrosi-
dase gene (chromosome 1q22), and approximate genotype–
phenotype correlations can be applied.(1)
A clinical subclassiﬁcation has been applied that is based on
age of onset and the presence and severity of neurological
involvement. Infantile GD (type 2) is rare and causes death in the
ﬁrst 2 years of life: There is neuronopathic disease with bulbar
palsy, opisthotonus, and minor visceral enlargement. It is
invariably fatal and does not respond to either systemic or
intrathecal enzyme replacement therapy (ERT). Neurological
disease in children, adolescents, and young adults is termed
subacute neuronopathic (type 3). In such patients, neurological
disease is less severe and associated with supranuclear gaze
palsies, ataxia, a central defect of auditory processing, myoclonus,
and occasionally seizures. Subacute neuronopathic disease is not
always fatal and often improves with bone marrow (BM)
transplantation and ERT (nonneurological aspects only).(2,3)
The most frequent form of GD, in Europe and the Americas, is
the so‐called adult nonneuronopathic form (type 1). This disease is
found in all populations, but is overrepresented in Jews of
Ashkenazi origin, in whom a single mutation (p.Asn409Ser, formerly
called N370S) dominates. The enzyme deﬁciency in type 1 disease
is typically incomplete, with up to 20% of normal activity remaining.
Although the condition does not commonly aﬀect the nervous
system, visceral and skeletal manifestations are prominent.
Extrapyramidal disease resembling Parkinson disease develops in
midlife in approximately 5% of patients.(4,5)
The pathognomonic abnormality of GD is the presence of
storage cells, which are activated macrophages (Gaucher cells).
The Gaucher cells are found in the splenic sinusoids, replace
the Kupﬀer cells of the liver and alveolar macrophages of the
lung, and inﬁltrate the BM. Of all cell types, the macrophages
carry the greatest storage burden. The measurable remaining
enzyme activity is suﬃcient to catabolize the endogenous
turnover of glucosylceramide in other cells types, including
neurons (in type 1 disease), but is insuﬃcient to cope with the
greater ﬂux of the sphingolipid substrate in phagocytosing cells
exposed to the additional load associated with the lipid fraction
of membranes of engulfed cells. As a consequence, storage
macrophages undergo phenotypic changes that include not
only enlargement, but also alteration in cell‐surface receptor
expression, inﬂammatory cytokine and chemokine production,
and the secretion of enzymes, including proteases, into the
extracellular space. The immune phenotype of the character-
istic Gaucher cell is that of an “alternatively activated”
macrophage, usually associated with chronic inﬂammation
and scarring when seen in other disorders such as scleroderma
and sarcoidosis. As a result of tissue macrophage distribution,
splenomegaly is almost universal, with associated hypers-
plenism and thrombocytopenia. Anemia is less common, but
when severe, is associated with BM failure caused by the
inﬁltration and replacement of hematopoietic marrow. Pul-
monary inﬁltration and lymphadenopathy are infrequent
manifestations, usually in children with severe disease. Bone
manifestations are the subject of this review and are discussed
in detail below.
GD is accompanied by many plasma and metabolic
derangements. These can include, in decreasing order of
frequency, a polyclonal increase in immunoglobulins, mono-
clonal gammopathy, multiple myeloma, and B‐cell lymphoma—
conditions that are important causes of death in adult patients
with type 1 GD; their cause is unknown. Low‐density lipoprotein
and high‐density lipoprotein cholesterol fractions are abnormal
in the plasma. The basal metabolic rate is increased. Some
lysosomal enzymes are elevated in the plasma, including
angiotensin‐converting enzyme, tartrate‐resistant acid phos-
phatase, and hexosaminidase, members of the cathepsin family
of proteases, and a human chitinase, chitotriosidase. Chitotrio-
sidase has proved to be very useful for monitoring GD activity
in response to treatment and may reﬂect the severity of the
disease. The concentration of this enzyme is sometimes
elevated by a factor of several hundred above normal in
untreated GD.
The mean age of death in a single large series was 60
years(6,7) during the pretreatment era, but this longevity does
not take into account the poor quality of life of most aﬀected
individuals. Some patients homozygous for “mild” missense
mutations in the glucocerebrosidase gene may escape
detection and remain asymptomatic throughout a long
adult life.
The diagnosis of GD is based on glucocerebrosidase activity
measured in leukocyte preparations, whereas spleen tissue,
liver biopsy material, or BM aspirates may show the character-
istic, generally oligonucleate, storage cells demonstrating
striated cytoplasm on Leishman staining or pink sheets in
tissue sections stained with H&E. Molecular analysis may
identify mutant glucocerebrosidase alleles that cause this
disease and may assist in the diagnosis and investigation of
family members at risk of this recessive disorder.
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Before the advent of ERT, treatment for GD was palliative and
supportive: This remains the case in much of the developing
world. It has been estimated that only 10% of potential patients
worldwide are receiving speciﬁc treatment.(8) BM transplanta-
tion has been undertaken in a few infants and children with
rapidly progressive disease, including those with the subacute
neuronopathic form, type 3. BM transplantation is no longer in
routine use because of the accompanying risks of the
procedure and constraints in the supply of donors.
Patterns of medical care clearly vary throughout healthcare
systems worldwide. Patients are most often under the principal
care of hematologists, metabolic specialists, geneticists, pedia-
tricians, gastroenterologists, or rheumatologists. Supportive
care is also provided by orthopedic surgeons, neurologists, and
other specialists.
The ﬁrst ERT, alglucerase (Ceredase; Sanoﬁ Genzyme, Cambridge,
MA, USA), was introduced in 1991 in the form of the physiological
enzyme extracted from human placenta and modiﬁed to reveal
terminal mannose residues. A recombinant form, imiglucerase
(Cerezyme; Sanoﬁ Genzyme), that is similarly modiﬁed for eﬀective
macrophage targeting became available in 1997. After a few
months of enzyme administration, most patients show an
improvement in the blood parameters of disease activity: The
platelet count rises, with a reduction in hepatosplenomegaly and
an improvement in the severe fatigue that accompanies GD.
Quality‐of‐life measures also show clear improvement in clinical
studies. Similar eﬀects are noted with the use of the more recently
licensed enzyme therapies velaglucerase (VPRIV; Shire Human
Genetic Therapies, Lexington, MA, USA) and taliglucerase (Elelyso;
Protalix Biotherapeutics, Karmiel, Israel). A detailed comparison of
speciﬁc treatment options is beyond the scope of this review.
At present, there is no agreed protocol for therapy in adults with
GD. However, the application of simple deﬁned therapeutic goals
with close monitoring of individual patients has much to
recommend it. Achievement of key goals and amelioration of
disease‐associated parameters is more rapid when the recom-
mended dose of enzyme therapy (approximately 60 U/kg every
other week) is administered. ERT, although very expensive (as much
as €258,000/US$288,000 per year),(9) is a successful treatment for
GD. Hypersensitivity and immune reactions are very rare, and many
patients in diﬀerent countries receive therapy at home.
In response to the inconvenience of parenteral administration,
there have been initiatives to develop alternative treatments,
including the use of oral agents that inhibit the formation of the
substrate delivered to macrophages. The ﬁrst such agent approved,
miglustat (Zavesca; Actelion Pharmaceuticals, San Francisco, CA,
USA), reduced the sphingolipid content of circulating white cells
and hadmodest eﬀects on laboratory and clinical parameters of GD
activity. Miglustat is licensed in the United States and Europe for
use in patients with mild‐to‐moderate type 1 GD for whom ERT is
unsuitable. The occurrence of peripheral neuropathy after long‐
term administration in a few patients and short‐lived unwanted
side‐eﬀects, including diarrhea, may restrict the indications for its
use. Additional orally active compounds are now authorized: The
substrate‐reducing agent and ceramide analogue eliglustat (Cer-
delga, developed by Sanoﬁ Genzyme) has shown beneﬁcial eﬀects
similar to those of enzyme therapy and has demonstrated good
eﬃcacy against aspects of bone disease in clinical trials.
Bone disease in GD patients
Skeletal manifestations are prevalent at all ages and are the
principal cause of pain, disability, and reduced quality of
life.(10–12) However, there remains a need for uniform recom-
mendations for bone disease evaluation and management.(12,13)
Physicians, including pediatricians, may be unfamiliar with bone
pathophysiology and the complexity of the skeletal manifesta-
tions arising throughout life. There is a need to enhance
awareness and to improve diagnosis, characterization, quantiﬁ-
cation, and treatment of skeletal and BM pathology in patients
with GD.
GD aﬀects the BM and the mineralized components of bone.
Changes include (1) BM inﬁltration and plasma cell dyscrasias;
(2) modeling and remodeling abnormalities of bones, resulting
in developmental changes and loss of bone mineral (osteo-
penia/osteoporosis), cortical thinning, lytic lesions, and fragility
fractures; and (3) osteonecrosis and related phenomena
(medullary infarctions, osteosclerosis, cortical infarcts, and joint
destruction and deformities).
Histopathological examination reveals not only Gaucher
cells, but also osteolytic lesions, necrosis, ﬁbrosis, loss of
trabecular bone, and failure of hematopoiesis. Bioactive
sphingolipids induce a cascade of changes that aﬀect bone
vascularity, intramedullary pressure, the immune environment,
hematopoiesis, and the function of cells that reside in bone,
ultimately disturbing skeletal growth and bone modeling and
remodeling.(14) Several of these eﬀects (eg, marrow inﬁltration
by pathological macrophages and osteopenia) are modiﬁed by
speciﬁc therapies, but the underlying pathophysiology of bone
disease remains poorly understood. Clearly, secondary changes
(complications, not universally present, but which ensue in
some patients—eg, osteonecrosis) and tertiary changes
(chronic manifestations of the secondary changes, such as
osteoarthritis, fracture deformity, and joint replacement) are
not reversed by speciﬁc disease‐modifying treatment.(14)
Of 2004 patients enrolled in the International Collaborative
Gaucher Group (ICGG) Gaucher Registry from 1991 to 2000,
between 76% and 94% of those with GD type 1 (GD1) had a
radiological manifestation of bone disease, including marrow
inﬁltration, Erlenmeyer ﬂask deformity, or osteonecrosis.(15)
Bone disease is often asymptomatic(15) and may sometimes
progress despite apparently eﬀective disease‐modifying
treatment.(16,17)
Objectives
To develop useful guidance in the assessment and manage-
ment of bone manifestations of GD for the practicing clinician,
we—an international group of physicians collectively having
treated over 1500 patients and having published over 150
articles on GD and bone complications of GD—met in
Amsterdam, Netherlands, in May 2016 (a meeting ﬁnancially
supported by Sanoﬁ Genzyme). In the preparatory phase of the
meeting, a comprehensive review of the literature was done by
a broad search using Embase and PubMed (January 1995 to
December 2015) for published articles with the terms “Gaucher
disease” and “bone” diseases, including related terms and
synonyms, which resulted in 521 articles. International congress
abstracts indexed in Embase from 2014 to April 2016 were also
included. All abstracts were prescreened for original and clinical
data (resulting in 290 remaining references) and reviewed by
topic groups of two or three experts and focusing on four
major topics: BMD, osteonecrosis, BM disease, and other bone
publications. Each topic group reviewed the articles for
relevance of information and quality of evidence to support
statements on natural history, monitoring, and treatment
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recommendations. At the face‐to‐face meeting in Amsterdam,
the morning was used to present and complete all key ﬁndings
and outcomes of the four topic groups to the whole group and
to discuss perspectives and interpretations. The afternoon was
used to complete missing data and to discuss and vote on best
recommendations. We found that the division into four topics
was somewhat artiﬁcial and overlapping; therefore, we decided
to organize best practices and unmet needs in GD‐related bone
disease into three key skeletal compartments: (1) the bone
marrow (Gaucher cell inﬁltration, macrophage function, osteo-
clast diﬀerentiation, interactions among bone and marrow or
immune cells, soluble messengers and biomarkers, ﬁbrosis, and
extraosseous “Gaucheromas”); (2) trabecular and cortical bone
modeling and remodeling defects, delayed bone growth, and
bone mineral loss and their consequences; and (3) medullary
and cortical bone infarction (osteonecrosis, osteosclerosis, acute
and chronic infection, and bone and joint deformity). The
structure of the discussion and the division into three
compartments was driven by an attempt to link elements of
bone involvement according to putative pathogenic mechan-
isms rather than morphology, and to clarify and standardize the
terminology of GD bone involvement. In most areas, consensus
was reached by weighing arguments, clinical experience, and
the available literature to set out practical recommendations.
When it was clear that agreement could not be achieved, we
identiﬁed aspects of GD‐related bone disease that are not fully
characterized or remain controversial.
The Bone Marrow
In patients with GD, organs containing mononuclear phagocytes,
including the BM, liver, and spleen, are inﬁltrated by enlarged,
glycosphingolipid‐laden macrophages called Gaucher cells.(18)
Gaucher cells are described as having an eccentric nucleus and
a striated (or “crumpled silk”) cytoplasm,(19) but atypical variants
(eg, multinucleated forms, erythrophagocytotic cells, cells with
foamy cytoplasm) exist in untreated patients and may confound
the diagnosis.(20) However, Gaucher cells are not pathognomonic
of GD (“pseudo‐Gaucher” cells are sometimes found in the
marrow of patients with myeloma and acute leukemias, for
example), and the diagnosis is dependent on the demonstration
of deﬁcient glucocerebrosidase activity in leukocytes, cultured
skin ﬁbroblasts, or dried blood spots.(21)
Gaucher cells progressively and centrifugally displace the
normal, triglyceride‐rich adipocytes from the adult marrow,(22)
initially in the axial skeleton and ﬁnally in the extremities.(18)
This replacement occurs in the opposite direction to the
physiological replacement of red, hematopoietic marrow by
the fatty marrow as part of normal development—thus
complicating evaluation in young people. The inﬁltrative
process is established early in the course of the disease and
usually before bone symptoms develop.(23)
Pathogenesis
Although individuals with extensive inﬁltration of the marrow
by Gaucher cells are more likely to suﬀer bone complications, it
remains unclear how the inﬁltration aﬀects BM organization
and function.(18,24)
In human cell‐culture studies, erythropoiesis, myeloid pro-
liferation and diﬀerentiation, and mesenchymal stem cell
development are impaired by inhibition of glucocerebrosidase
before pathological glucosylceramide storage is detected and
morphological changes occur.(25) Hematopoiesis may be down-
regulated by various bioactive glycosphingolipids whose
intracellular levels and relative proportions are abnormal in
GD.(25) Hematopoiesis and skeletal remodeling may also be
aﬀected by the displacement of normal BM adipocytes by
Gaucher cells.(22,26) BM mesenchymal stromal cells (which give
rise to the bone‐forming osteoblasts, the osteocytes, and bone‐
lining cells, as well as BM adipocytes) have been reported to
have an altered cytokine‐ and prostaglandin‐expression proﬁle
(the inﬂammatory secretome). These changes may promote not
only reduced BMD, by increasing osteoclast numbers and
activity, but also proliferation and activity of plasma cells,
and thus the generation of polyclonal and monoclonal
gammopathies.(27)
GD is associated with an increased risk of cancer in general
(relative risk 1.7 compared with the general population) and
BM‐based hematological malignancies (estimated risk 3.5 to
12.7) in particular, speciﬁcally multiple myeloma (estimated risk
25.0 to 51.1).(28,29) The clonal immunoglobulin in GD patients
binds to glucosylsphingosine,(28–30) concentrations of which are
greatly increased in GD patients as a direct consequence of
glucocerebrosidase deﬁciency.(31)
Histological and imaging ﬁndings
The histological appearance of inﬁltrated BM is heterogeneous,
and pathological examination of the femoral head reveals areas
of vital bone adjacent to Gaucher‐cell‐inﬁltrated marrow, areas
of nonspeciﬁc chronic inﬂammation and ﬁbrosis, islands of
necrosis in osteocyte‐free areas of avital bone, and areas of
normal hematopoietic marrow.(32) Nevertheless, it remains
unclear whether the severity of bone disease is correlated
with the extent of Gaucher‐cell inﬁltration(33,34) or their
particular features.
In adults, marrow inﬁltration by Gaucher cells can be seen by
MRI, in which T1‐weighted spin‐echo sequences show areas of
reduced signal intensity known as dark marrow, reﬂecting
greater water content. The amount and distribution of dark
marrow seen by MRI reﬂect the extent of inﬁltration of the BM
by Gaucher cells (containing water) as they displace the fat in
the marrow compartment.(18,24) The pattern of inﬁltration
provides information about disease severity: an inhomoge-
neous (type B) pattern has been described to reﬂect greater
irreversibility of disease than a homogeneous type A
pattern.(24,35) The extent of BM inﬁltration can be evaluated
by quantitative chemical shift imaging (QCSI),(36) which allows
measurement of the fat fraction of BM in the vertebrae. A fat
fraction less than 0.23 is associated with bone complications.(24)
However, QCSI is complex, expensive, and of very limited
availability.(24)
In common practice, the extent of BM inﬁltration by Gaucher
cells is evaluated semiquantitatively from MRI data of the spine,
pelvis, and lower limbs by using one of several scoring systems.
The systems most widely used in clinical practice include the
Bone Marrow Burden (BMB) score, which correlates well with
fat fraction measured by QCSI,(36) the Düsseldorf Gaucher Score
(DGS),(35,37) and the vertebra‐to‐disk ratio (VDR).(38) The BMB
score, DGS, and VDR have shown utility for the radiological
follow‐up of BM inﬁltration in multiple studies.(39) Other bone
disease scoring systems are used less frequently.(40–45) An
estimation of disease severity based on hematological and
visceral manifestations, as well as bone manifestations, is
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provided by the GD1 disease‐severity scoring system (GD1‐
DS3), in which 42% of the total score is determined by bone
manifestations (hematological manifestations provide 32% and
visceral manifestations 26% of the total score).(46) The Italian
Gaussi‐I severity scoring system proposed a clinically useful
categorization of the various BM inﬁltration scores.(47)
MRI‐based scoring of marrow inﬁltration is not as reliable in
children and young adults as in mature adults. Values of the
BMB score, DGS, and VDR do not accurately reﬂect clinical
status in younger patients because of their higher proportion of
hematopoietic (rich in water and poor in fat) marrow.(39)
However, the VDR, which changes with age and ﬂuctuates
according to the water content of the intervertebral disk, is
more reliable in younger patients because they lack the disk
degeneration seen in older patients.(39) In children, vertebral
BM inﬁltration can also be evaluated by measuring the
apparent diﬀusion coeﬃcient, a parameter that correlates
inversely with several markers of GD severity.(48)
BM inﬁltration may also be reliably represented by scinti-
graphy using the lipophilic cationic agent 99mTc‐sestamibi,(49)
and a normalized score has been proposed that takes into
account the values from several MRI‐based scoring systems and
the scintigraphic score.(50,51) Scintigraphy using 99mTc‐sestamibi
provides an alternative method by which to evaluate marrow
inﬁltration in children, but is not widely available and involves
radiation exposure.
The replacement of marrow fat by GD‐related tissue may be
exaggerated in the presence of massive splenomegaly with
anaemia: Appreciable red cell pooling because of hypers-
plenism stimulates erythropoietin release and an element of
erythroid expansion.(18)
Treatment and response evaluation
Approved treatments available to date for GD1 are the ERTs
imiglucerase, velaglucerase alfa, and taliglucerase alfa (the last
not approved in the EU) and the substrate‐reduction therapies
(SRTs), eliglustat and miglustat. These have been reviewed in
detail elsewhere.(11) Realizing that relevant diﬀerences between
the various molecules may exist, we would like to emphasize
that for ease of reading, here we have used the umbrella term,
ERT. Most experience has been gathered with imiglucerase(52);
we therefore recommend reviewing the cited references and
the local label when considering a particular treatment for
potential beneﬁts in bone biology and clinical eﬃcacy.
Bone complications respond to ERT more slowly than visceral
and hematological manifestations of GD.(53) The BMB score has
been shown to improve by 2 or more points in patients
receiving ERT(54) and appears to stabilize after 5 years of
therapy,(55) reaching near‐normal values after 7 years of ERT.
However, an increase in the fat fraction measured by QCSI has
been reported to occur within a year of ERT.(56) In children
receiving ERT, most clinical parameters (including BMD) have
been reported to normalize or near‐normalize within 8 years.(57)
In treatment‐naïve adults in clinical trials of eliglustat, mean
BMB score improved by 2 points after 18 months of eliglustat
therapy,(58) and mean LS T‐scores moved from the osteopenic
range to the normal range after 2 years; improvement
continued for up to 8 years.(59) Gaucher cell inﬁltration in the
femur, as shown by the amount of dark marrow, has been
shown to decrease or remain stable with eliglustat.(59) In adults
with GD1 who switched to eliglustat after having been
stabilized on long‐term ERT (mean of 10 years), a repeated
measures, mixed‐model analysis showed that the least‐square
mean LS Z‐score, which was in the normal reference range at
baseline, increased by 0.29 (P < 0.001) after 4 years of eliglustat
therapy.(60)
Our recommendations
Diagnosis of BM inﬁltration
Initial and serial measurement of blood counts is standard
practice for evaluating disease severity and response to
treatment. Thrombocytopenia is mainly attributable to hypers-
plenism, as shown by near‐invariable normalization after
splenectomy, whereas BM dysfunction is more relevant to
anemia. Chitotriosidase can be a valuable marker for serial
assessment of GD patients,(23,61–63) but activity is related to the
total burden of storage, not speciﬁcally bone pathology. In
patients genetically deﬁcient in chitotriosidase activity, the
chemokine CCL18/PARC can be used to monitor therapeutic
response. Serum glucosylsphingosine shows promise as a
reliable and speciﬁc biomarker for both diagnosis and
monitoring of treatment response in GD.(64–66)
A BM biopsy is not necessary for diagnosis or monitoring of
GD, but may be appropriate in a patient in whom hematolo-
gical malignancy is suspected. Assessment of serum immuno-
globulins, serum‐free light chains, and urinary Bence‐Jones
proteins may suggest a diagnosis of myeloma. Diagnosis of
myeloma by microscopic cytological examination can be
hindered by large numbers of Gaucher cells. Plasma cells may
be atypical; identiﬁcation of intracytoplasmic immunoglobulin
may help to distinguish plasma cells from Gaucher cells.
MRI can provide semiquantitative assessment of marrow
inﬁltration, an insight into the degree of reversibility of the
marrow inﬁltration. An inhomogeneous pattern of marrow
inﬁltration is associated with the presence of bone infarction.(67)
Monitoring and scoring
Our recommendations for monitoring the BM are shown in
Table 1. MRI is the gold standard for monitoring bone
involvement in GD patients, taking into account the patient’s
age. Below 19 years, we suggest including tibiae (BM in tibiae is
converted to fatty marrow around age 9 years). Below age 9, it
is very diﬃcult to assess red marrow inﬁltration. Although plain
radiography is not as sensitive or precise as MRI or DXA, it can
provide useful and clinically meaningful information in loca-
tions where MRI and DXA are not available. In this instance,
children should be assessed annually and the radiographs
evaluated by an orthopedist or radiologist experienced in
GD.(68) The utility of whole‐body MRI,(24) proton MR spectro-
scopy,(69) and QCSI is theoretical because the availability of
these modalities is limited. Data on the use of CT‐PET and MRI‐
PET in GD are limited.
Treatment
Whether the treatment of choice is ERT or SRT, prompt
initiation is key to optimizing outcomes.(14,70)
For physicians who are relatively inexperienced in treating
GD, we encourage multidisciplinary collaboration to facilitate
clinical decision‐making; the team should include a radiologist
experienced in GD.
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In case of a malignancy, treatment should follow guide-
lines appropriate for the tumor type, taking into account
the complexities of GD, and care should be taken to
optimize BM function in relation to the delivery of
myelotoxic chemotherapy.(71) The presence of GD in itself
should not, however, inﬂuence the decision to treat the
malignancy.
Remaining unmet needs
Speciﬁc biochemical markers of Gaucher cell‐related bone
disease are needed to allow frequent noninvasive monitoring
of bone pathology and its response to therapy.(14)
Although understanding of the pathophysiology of GD‐
related malignancy has recently advanced, further work is
required to facilitate the targeted intervention and prevention
of this disease manifestation.
Trabecular and Cortical Bone: Modeling and
Remodeling Defects
This category of GD‐related bone disease was created to bring
together those features linked by the putative common
pathological mechanism of imbalance between bone forma-
tion and breakdown, between the actions of osteoblasts and
osteoclasts. Here we include a disorder of primary bone
modeling that takes place as part of long bone growth: the
Erlenmeyer ﬂask deformity. We also include the spectrum of
diﬀuse low BMD found in patients with GD as measured by
DXA, cortical bone thinning, and consequential fragility
fractures and focal osteolytic lesions.
Modeling and remodeling defects
Long bones include the diaphysis (the hollow shaft), ﬂared
metaphyses below the growth plates, and the epiphyses above
the growth plates. With the cessation of endochondral
ossiﬁcation at the growth plates and consequent fusion of
the metaphyses and epiphyses at the end of adolescence,
longitudinal bone growth ends. Children with severely
symptomatic GD often have retarded growth as well as delayed
puberty. Although bone growth may accelerate with the
eventual onset of puberty, some children continue to have
short stature as adults. When ERT is begun before growth plate
closure, most children and adolescents with GD reach their
expected midparental height.(57,72,73)
Bones also undergo radial growth that is determined by a
net excess of new periosteal osteoblastic bone formation over
endosteal osteoclast‐mediated bone resorption.
To accommodate biomechanical stresses, long bones typi-
cally undergo an osteoclast‐driven modeling process and
change in shape and contour. This process also primarily
occurs during childhood and adolescence.(74)
Erlenmeyer ﬂask deformity
One outcome of defective modeling based on BM inﬁltration in
GD is the Erlenmeyer ﬂask deformity, which starts before
puberty.(11,14) The ﬂask‐like appearance (Fig. 1) results from
enlargement of the metaphyseal area and consequent absence
of the typical concave dimetaphyseal curve.(11,14) The defor-
mity, generally asymptomatic, can be seen in many of the
tubular or long bones of the skeleton, occasionally even the
phalanges, in GD patients, but it does not aﬀect bones that
arise in membranes (eg, the skull vault). Although it is reported
in up to 80% of adults with GD1, principally at the lower femur,
and may provide a diagnostic clue, the Erlenmeyer ﬂask
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Fig. 1. Erlenmeyer ﬂask deformity. (A) Typical appearance. Radiograph of the lower femora, showing the triangular outline of the metaphysis. Note
the indistinct boundary between the cortex and medulla, typical of the Erlenmeyer ﬂask deformity in Gaucher disease (GD). Incidentally, there is an
area of serpiginous sclerosis in the left femoral metaphysis, suggestive of osteonecrosis. (B) Atypical appearance. Radiograph of the lower femora of a
woman with GD who began enzyme replacement therapy at the age of 12 years. The proximal metaphysis has features similar to those in A, but the
distal metaphysis has the more normal, trumpet‐shaped outline of the distal femur, with a clear border between the cortex and medulla. We
speculate that the normal modeling process of endochondral ossiﬁcation took place from the time of initiation of therapy
deformity is not unique to GD, and its signiﬁcance is
uncertain.(11,12,14) Deﬁnition and quantiﬁcation of the abnorm-
ality have been attempted.(75)
The sign is also observed in other bone diseases(76–80) in which
osteoclast function is thought to be impaired. It is present
in a mouse model deﬁcient in tartrate‐resistant acid phosphatase,
an enzyme essential for the resorptive function of osteoclasts.(81–83)
The clinical signiﬁcance of the Erlenmeyer ﬂask deformity is
unclear. To date, it has not been found to be associated with
fragility fracture or osteonecrosis.(84)
Osteopenia and osteoporosis
The bone turnover cycle
Throughout life, bones are constantly remodeled to maintain
mineral homeostasis and preserve bone strength by repairing stress
microfractures. Osteocytes, about 90% of adult skeleton cells,
function as a mechanosensor and send signals to both osteoclasts
and osteoblasts to remodel or maintain bonemass. The remodeling
process involves tight coupling of osteoblast–osteoclast function
and is regulated by the ratio of RANKL to osteoprotegerin (OPG):
High OPG levels protect against excessive osteoclastic bone
resorption.(85) Sclerostin (an inhibitor of osteoblastic activity),
prostaglandin E2 (a stimulator of osteoblast activity), cytokines
(IL‐1, IL‐6), the protease cathepsin K, parathyroid hormones,
estrogen, vitamin D [1,25(OH)2D3], and osteocalcin are also
well‐known players in bone turnover, which determines bone
mass and strength. The β‐catenin signaling pathway plays an
essential role in bone growth and development. Targeted deletion
of β‐catenin in osteocytes results in a fragile, porous skeleton highly
susceptible to fracture.(86)
An excess of osteoclastic bone resorption over osteoblastic
bone formation leads to net bone mineral loss. Imbalanced
bone remodeling and bone mineral loss characteristically occur
in postmenopausal women and, to a lesser extent, in ageing
men and sedentary people.(74)
Experimental evidence in GD
Experimental studies provide support for the role of aberrant
osteoblastic and osteoclastic activity in the development of
osteopenia and osteoporosis in GD. Other cells, including
mesenchymal stem cells, may also be adversely aﬀected by the
lipid accumulation that characterizes GD.(87)
In tissue culture, glucocerebrosidase‐deﬁcient peripheral
blood mononuclear cells (PBMCs) diﬀerentiate into osteoclasts
more rapidly and more vigorously than do monocytes with
normal glucocerebrosidase activity, and the functional bone
resorptive capacity of glucocerebrosidase‐deﬁcient osteoclasts
in vitro is enhanced relative to their normal counterparts.(88)
Also, in ex vivo cell cultures and in vivo experiments in
irradiated mice, glucocerebrosidase‐deﬁcient mesenchymal
stromal cells (nonhematopoietic osteoblast precursors in the
BM) isolated from 10 patients with GD1 had impaired ability to
proliferate and diﬀerentiate into osteoblasts.(88,89)
Markers of osteoblast and osteoclast activity in GD patients
In the healthy population, markers of bone turnover are highly
expressed in childhood and especially during pubertal growth
acceleration. These osteoblast and osteoclast activity markers
decline after completion of growth.
The signiﬁcance of bone turnover markers in GD has been
explored, but ﬁndings so far reported are not conclusive,
possibly because of diverse experimental conditions and the
failure of several studies to take account of the eﬀects of age,
pubertal development, and treatment status. In one well‐
conducted case‐control study of children and adolescents with
untreated GD, serum concentrations of osteocalcin (a marker of
osteoblastic bone formation) and type 1 collagen C‐terminal
telopeptide (a marker of osteoclastic bone resorption) were
lower than those in controls and as low during childhood and
adolescence as in adulthood.(90)
Serum glucosylsphingosine may be a pathologically rele-
vant biomarker as it has been shown to mediate osteoblast
dysfunction in GD.(87)
Cathepsin K has been identiﬁed as the principal expressed
protein of the osteoclast.(27) Cathepsin K is highly active in the
cleavage of the bone matrix proteins collagen type 1 and
osteonectin, and its role in bone resorption, modeling, and
turnover has been clearly demonstrated.(91) Enhanced cathe-
psin K expression has been observed in patients with GD.(92)
This perturbation of bone remodeling in GD1 may result in a
failure to achieve a peak bone mass equivalent to that of
normal adults.(93) Whether there is a mechanistic link between
pubertal delay in GD (discussed in the Modeling and
remodeling defects section) and the suppression of bone
turnover needs to be established.
Other factors aﬀecting bone health
There is a general appreciation that vitamin D concentrations
are low in GD. Mikosch and colleagues measured concentra-
tions of 25‐OH vitamin D in 74 GD patients in the UK at several
points throughout the year.(94) They found a high prevalence of
low vitamin D concentrations, according to a range of cut‐oﬀ
points. Vitamin D concentrations correlated weakly with bone
density measurements, with some seasonal and inverse
correlation between vitamin D and parathyroid hormone,
indicating that, at least in the winter months, vitamin D
deﬁciency was of physiological importance.
Measurement of bone mineral mass
Low bone mineral mass can be detected by bone densitometry
(ie, DXA) as a reduction in BMD.(15) DXA should be performed at
the LS (L1 to L4) and hip (total hip or femoral neck) in adults
and lumbar + (total body‐minus‐head) in children, considering
methodological precision and least signiﬁcant change detect-
able by individual equipment. The minimum age for densito-
metric examinations is 5 years. The parameters obtained from
DXA measurements are bone mineral content (BMC) in grams,
area in cm2, and BMD in g/cm2. DXA should be interpreted
using the Z‐score (diﬀerence between the individual’s mea-
sured value of BMD and the normal population mean) as a
reference value in younger individuals.(95,96) Z‐scores below ‐2
indicate reduced BMD.(97) In postmenopausal women and in
men older than 50 years, BMD is expressed in terms of the
T‐score (calculated in relation to young adults of the same
sex)(84) and is interpreted using the WHO classiﬁcation of
osteopenia and osteoporosis, which deﬁnes osteopenia as a T‐
score between ‐1 and ‐2.5(98) and osteoporosis as T‐scores less
than ‐2.5. In children, the total‐body‐minus‐head scan is
mandatory; measurement of femoral BMD is not reliable
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because of the high variability in skeletal maturity, bone size,
and pubertal stage.(99)
Bone mineral assessment and risk of fracture in GD
An analysis of data from the ICGG Gaucher Registry has shown
that a low BMD of the LS is associated with a high risk of
fracture of the spine or femur in GD1 patients.(10) ICGG Gaucher
Registry data also indicate that 55% of all registry patients have
investigator‐deﬁned osteopenia.(100) In one study, fragility
fractures were reported in 28% (cumulative incidence) of 100
adult GD patients of median age 49 years (range 19 to 85
years).(84) This ﬁgure may be compared with an 18% cumulative
incidence of fracture (presumably traumatic and fragility
fractures combined) in a separately published, large control
group of a similar age and sex distribution.(101) It is possible
that ICGG Registry data represent an underestimate of the
fracture prevalence in GD patients because asymptomatic
vertebral fractures may not have been recorded.
A Z‐score of ‐1 or less in GD patients increases the risk of a
fragility (low trauma) fracture by a factor of 5,(12,70) which is a
signiﬁcantly higher estimate than that commonly associated
with osteoporotic fracture in population studies.(102)
A BMD below the expected range for chronological age
(Z‐score < ‐2.0) occurs early in patients with GD1 and may
become apparent by the age of 5 years.(52)
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Fig. 2. Osteonecrosis. (A) Typical. T1‐weighted MR image of the pelvis, showing a geographic area of low signal in the head of the left femur. Note
that the joint surface remains intact in this case; therefore, there is no deformity or degenerative change in the hip joint. (B) Atypical. T1‐weighted MR
image of the pelvis in a diﬀerent patient showing diﬀuse low geographic area of low and high signal through the pelvic bones bilaterally. The
radiologic changes in (B) occurred gradually over years, on enzyme therapy, and without the typical symptoms of bone crisis
Fig. 3. The lumbar spine of a patient with GD and recurrent bone crises despite therapy. All images taken several years after last acute bone crisis.
(A) DXA image. Note the increased BMD in L3 and L4. These vertebrae were not excluded from the report, despite the variation in BMD among
vertebrae, contrary to best practice. The total lumbar vertebral BMD reported is therefore artifactually elevated. (B) T1‐weighted MR image showing
widespread, low‐signal geographic changes in L4, L5, and the sacrum, features indicative of osteonecrosis. Central endplate depression is also seen.
(C) T2‐weighted image showing double‐line sign indicative of osteonecrosis best seen in S1 and S2 segments and areas of low signal in the bodies of
L4 and L4. Low signal in both T1‐ and T2‐weighted images indicates osteosclerosis. (D) Plain anteroposterior lumbar spine radiograph in the same
patient show osteosclerosis of the body of L4. The increased density at L4 and L5 is therefore a result of osteosclerosis, consequent upon
osteonecrosis, although a contribution from endplate depression cannot be excluded
In adults with GD the average lumbar BMD Z‐score is
approximately ‐1.0, but with a wide distribution.(52) Patients
who have undergone splenectomy have a lower bone density
than nonsplenectomized patients,(95) but it is not clear whether
this is simply a reﬂection of greater disease severity or an eﬀect
of splenectomy.
Assessment of bone mass by DXA in GD may be complicated
by focal anatomical changes and focal disease. Osteonecrosis of
the femoral head (Fig. 2A) with subsequent sclerotic and
arthritic changes makes assessment of that site by DXA
inappropriate, and compressed fractured vertebrae need to
be excluded. Changes in the water and fat composition of the
marrow may also aﬀect the measured BMD, as certain
assumptions are made regarding the marrow fat content that
may not be true in GD. What may be less obvious to DXA
practitioners who are unaccustomed to GD is that osteone-
crosis can take place within the vertebral bodies and may result
in sclerosis (Fig. 3 A‐D), and that relatively small areas of bone
within the ﬁeld of view of DXA scans can undergo necrosis and
sclerosis, giving rise to a step‐change increase in BMD. Other
confounding factors in DXA measurements in adults include
the presence of osteophytes, vascular calciﬁcations, and calculi,
which can lead to overestimation of bone mass. It should
also be recalled that the DXA score is only one of many
determinants of fracture risk that include such elements as
smoking status, alcohol consumption, physical activities, use of
concurrent medications, and vitamin D deﬁciency.
Osteolytic lesions
Focal osteolytic lesions (also called lytic lesions; Fig. 4) are
uncommon in GD1 patients.(84,100,103) They are thought to be
caused by the action of cysteine proteases secreted by Gaucher
and related cells(27) in areas where the intermedullary space is
tightly packed with inﬁltrated macrophages.(11) They have a
typically “worm‐eaten” appearance because of a rareﬁed cortex
and dentate endosteum; the cortical thinning (Fig. 5A, B) is an
important risk factor for fractures.(11,12)
It is important to diﬀerentiate GD‐related osteolytic lesions
from those occurring in malignancies (eg, multiple myeloma,
plasmacytoma).(11)
Kyphosis and gibbus deformity
Thoracic kyphosis may develop in any patient with GD as a
result of vertebral fragility fractures resulting from low bone
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Fig. 4. CT image of the right hip, showing a lytic and expanding lesion
(Gaucheroma) of the greater trochanter, superiorly displacing
fragments of bone
Fig. 5. Plain radiographs of the proximal left femora of two patients with Gaucher disease. (A) Normal cortical thickness in the femoral shaft of the left
proximal femur. (B) Reduced cortical thickness in the femoral shaft of the left proximal femur. Note the thinner cortex in comparison with A
mass. There is, however, a distinct entity, gibbus deformity
found in many patients with chronic, neuronopathic (type 3)
GD (especially those homozygous for L444P) that manifests as a
sharply angulated deformity of the spine, usually at the
thoracolumbar junction (Fig. 6). This deformity usually develops
in late childhood or early adolescence and can give rise to
severe height loss, chest wall deformity, and restricted
breathing. Many patients undergo corrective surgery using
metal Harrington rods and spinal fusion. The cause of the
gibbus deformity is debated and unclear, but it does not
correlate with other skeletal manifestations of GD and is
apparently not preventable with ERT.
Our recommendations
Monitoring and scoring
In asymptomatic adult patients, we recommend careful DXA of
the LS and left and right hips, considering potentially
confounding focal disease (see Table 1). For children, total‐
body‐minus‐head DXA is required. Serial DXA evaluations
should consider the Z‐score (or T‐score), BMD, and BMC.
When considering the relation between GD and fracture,
it is important to exclude the inﬂuence of comorbidities
that increase the fracture risk (eg, multiple myeloma,
steroid use).
We recommend not using QCT of the LS routinely to avoid
unnecessary radiation exposure, although it may occasionally
be helpful in resolving questionable DXA results and to assess
critical cortical‐thinning associated with lytic lesions. We also
recommend not using ultrasonography for the assessment of
bone density and quality.
Treatment
In general, optimal skeletal health should be ensured by
following common clinical practice, including adequate cal-
cium and vitamin D therapy according to local guidelines.
Improvement in osteopenia has been widely reported in GD
patients treated with ERT or with SRT in observational studies
and in clinical trials. ERT improves bone mass in all age groups:
The greatest eﬀect is seen in younger subjects during the
period when peak BMD is accrued.(52) Early and sustained
treatment is crucial, as a clear dose–response relation has been
demonstrated.(53) So far, no evidence has emerged for an eﬀect
of speciﬁc Gaucher treatment on the risk of fracture. A single
double‐blind, placebo‐controlled clinical trial has demonstrated
the eﬃcacy of oral bisphosphonate therapy in improving BMD
in GD.(104)
We believe that, in general, GD per se is not suﬃcient reason
for the use of systematic treatment with bisphosphonates, but
informed use of bisphosphonates should not be excluded in
patients with GD for appropriate treatment of any relevant
condition. The eﬀects and recommended administration of
new bone agents (eg, denosumab) have not been established
in GD.
Areas of controversy OR no consensus
The eﬀect of speciﬁc therapy on the evolution of the
Erlenmeyer ﬂask deformity is worthy of further study to help
elucidate the pathogenesis of abnormal bone development in
growing children with GD (see Fig. 1B).
In addition, further work is required to understand the
implications for GD of blood concentrations of vitamin D and
its metabolites.
Remaining unmet needs
Several publications report improvement in BMD as a result of
ERT or SRT.(18,63,105)
In children and adolescents, several studies have shown
apparent bone mass accretion upon institution of enzyme therapy,
with patients crossing centile lines for bone mass.(52,106) However,
the clinical signiﬁcance of these ﬁndings is not always clear, and
methodological issues (eg, use of retrospective analyses, technical
issues) and the absence of comparative data may be sources of
bias. In children, there is an additional confounder in that delayed
pubertal development and delayed growth are often ameliorated
with the use of enzyme therapy, so that it is not clear whether any
eﬀect on BMD is direct or related to changes in hormonal status
and bone growth.(72) We are concerned that the poor predictive
value of DXA for clinical outcomes is often ignored. Until a frank
evaluation of the predictive power of DXA for fractures in GD has
been performed, the use of DXA to predict the risk of fracture in
GD patients is limited. The need remains for better strategies for
determining bone integrity and fracture risk that are clinically
useful, safe and convenient, transferable, robust, and valid.
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Fig. 6. Lateral radiograph of the spine of a patient with type 3 GD,
showing an abruptly angulated thoracic kyphosis
Osteonecrosis
Natural history
Osteonecrosis, reported in up to 43% of adult GD patients in a
UK cohort,(84) can be seen as another consequence of the
inﬁltration of the BM by Gaucher cells.(18) New lesions can occur
at any time throughout life. Osteonecrosis is often multifocal
and may be associated with puberty or pregnancy.(107) It
signiﬁcantly impairs quality of life for GD patients, commonly
causing chronic pain and disability and leading to the need for
surgical intervention.(108)
Deﬁnition of terms
Osteonecrosis
The terms osteonecrosis, avascular necrosis, aseptic osteone-
crosis, and bone infarct are used variably in the GD literature.
They all describe the same clinical condition, though in
some cases they depend on the anatomical location of the
lesion. The etiology of this condition in GD is not clear, and any
assumption of arterial insuﬃciency is not warranted; therefore,
we prefer the term osteonecrosis.
This condition develops over weeks to months and has
characteristic features on MRI that also evolve over time
(Fig. 2). We contend that the location of the lesion is irrelevant
to the terminology, although the location does inﬂuence the
risk of late complications because involvement of the articular
surface can lead to subchondral or joint collapse.
Bone crisis and infectious osteomyelitis
Osteonecrosis is often predicted by the occurrence of a bone
crisis.(11) This clinical event takes the form of acute, severe bone
or joint pain that is often associated with fever, edema, and a
local and systemic inﬂammatory response. The symptoms
are often immobilizing, requiring bed rest and opiate analgesia.
Clinically, bone crises can be confused with infectious
osteomyelitis.(109) In a bone crisis, no bacteremia is pre-
sent.(15,110) Generally used imaging methods such as MRI, but
also radionuclide bone and BM scintigraphy, can give informa-
tion to separate a bone crisis from infectious osteomyelitis at
an early clinical time point (1 to 3 days after pain onset).
Radionuclide bone scans are usually initially “cold” in Gaucher
bone crises, but “hot” in the presence of osteomyelitis. Detailed
information about radionuclide imaging in GD is summarized in
an overview by Mikosch et al.(111) In clinical terms, it is
important to note that bone crises are much more frequent
than infectious osteomyelitis in GD.
Pseudo‐osteomyelitis
This term is confusing and must be eliminated from our
vocabulary: it is a bone crisis.
Pathogenesis
The mechanism of osteonecrosis is less clear in GD than in
other disorders such as sickle cell disease and diving
decompression injury in which arterial obstruction is pro-
posed.(14) The Gaucher cells, engorged with glucocerebroside,
cause chronic inﬂammation with the production of several
cytokines that have key inﬂuences on the bone remodeling
process.(40) GBA1 genotype also has an inﬂuence, and
p.Asn409Ser (formerly known as p.N370S) homozygosity
appears to confer some protection against the early develop-
ment of bone disease,(40,42,67,112) though associated with
progressive skeletal disease of adult onset.(44,113)
D‐dimer
D‐dimer concentrations vary signiﬁcantly between patients,
depending on the presence or absence of osteonecrosis,
splenectomy, and treatment.(114) Signiﬁcantly higher concen-
trations of D‐dimer have been observed in GD patients than in
a control group and in GD patients with abnormal MRI ﬁndings
in the long bones than in those with normal long‐bone MRI
ﬁndings.(115) Presumably, these D‐dimer increases (along with
reported increases in thrombin–antithrombin complexes in
patients with osteonecrosis(116)) reﬂect a state of coagulation
activation, but whether they are contributory or consequent to
osteonecrosis remains unresolved.
Osteonecrosis is seen relatively frequently (46%) in patients
with radiologically deﬁned type B morphology (heterogeneous
BM inﬁltration) in comparison with only 3% in patients with
type A morphology.(24,117)
Splenectomy
Splenectomy is an important risk factor for osteonecrosis before
and even after initiation of ERT.(35,84,118) After removal of the
spleen, an overload of Gaucher cells occurs within the BM. It is
likely that the development of osteonecrosis after splenectomy is
facilitated by an alteration in thrombosis, thrombolysis, platelet
activation, and rheological parameters (eg, blood viscosity, red cell
deformability)(84,119,120) and an increase in the number of
microparticles that are normally cleared by the spleen.(121)
Splenectomized patients have a greater chronic inﬂammatory
burden and more severe bone disease than nonsplenectomized
patients.(67) It has long been debated whether the association
between osteonecrosis and splenectomy is causal or related to the
greater disease burden in patients requiring splenectomy. The
close temporal association between splenectomy and subsequent
osteonecrosis events(84) suggests a causal relation.
Therefore, splenectomy should be avoided to avert the
development of osteonecrosis.(40) On the other hand, sple-
nectomy does not appear to be causally linked to osteopenia,
further underlining the distinct pathophysiological mechanism
involved.(122) However, bone damage resulting from osteone-
crosis is a risk factor for pathological fracture in GD patients.(110)
Therapy
Delay in initiating speciﬁc treatment is also relevant to the
development of osteonecrosis.(123) Patients who start ERT
within 2 years of diagnosis have a signiﬁcantly lower risk of
osteonecrosis than do those who receive treatment 2 years or
more after diagnosis.(118)
Our recommendations
Monitoring and scoring
We recommend plain radiography as part of the baseline
assessment at diagnosis, for speciﬁc lesions, and as needed to
interpret DXA scans. Plain radiography should be performed in
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anatomical areas where patients are symptomatic. However, plain
radiography can detect only severe osteonecrosis with secondary
and tertiary changes; therefore, it is not valid for an early diagnosis
of osteonecrosis. MRI and scintigraphy are valid methods for
monitoring acute bone crises. Only with time does it become clear
whether an ongoing process in the bone is osteonecrosis rather
than reversible marrow edema: Damage remaining after several
years can be considered proof of osteonecrosis.
MRI, where available, should be repeated everyone to 2 years
and when indicated for clinical reasons (pain, trauma,
surveillance because of a history of osteonecrosis or sple-
nectomy, and in patients with high DS3 scores), whereas the
interval between two MRI scans may be increased in stable
patients treated for more than 5 years.(55) Expert guidance is
needed for the use of MRI in children.
Treatment
Osteonecrosis is always an indication for GD‐speciﬁc therapy
(ERT or SRT, even if no other criteria are fulﬁlled).
When a bone crisis occurs and MRI shows bone edema and
periosteal inﬁltration on STIR or T2‐fat‐saturated sequences,
bed rest to reduce the articular load can help to prevent
progression and to relieve symptoms. In addition, appropriate
analgesics, up to and including opioids, should be prescribed
on the basis of pain severity.
Historically, surgical therapy for fractures or joint defor-
mity has carried a risk of infections, particularly osteomye-
litis, often related to the spread of cutaneous staphylococcal
infection from indwelling cannula sites. Currently—and in
experienced centers—joint replacement in GD is safe, and
prostheses can function well for many years. Attention to risk
of bleeding and infection is crucial. Operative bleeding
caused by coagulation disorders and platelet dysfunction
occur particularly in patients with hepatic involvement and
in those who have undergone splenectomy. We advise extreme
caution in the use of invasive procedures in the context of acute
osteonecrosis in GD to reduce the risk of subsequent bone
infection. We suggest that it is safest to presume that an acute
onset of bone pain is related to osteonecrosis and to withhold
emergent invasive intervention such as decompression or
drainage, unless there is compelling evidence otherwise. We
recommend the use of antibiotics when invasive procedures are
unavoidable. Core decompression is not proven to be eﬀective;
therefore, we do not recommend it. Joint replacement may be
required for the relief of chronic pain.
Remaining unmet needs
Risk factors such as anemia,(10) iron metabolism, cytokine
expression, and genotype have not been conclusively corre-
lated with osteonecrosis and should be investigated further.
Further investigation is needed to determine whether
disease recurrence or progression on enzyme therapy depends
on the ERT dose or occurs as a result of “treatment resistance.”
If treatment resistance does occur, a biomarker is needed to
predict its development. We should also consider the
possibility of poor tissue penetration to local areas and disease
“sanctuary sites” such as bone. It remains to be seen whether
small molecule treatments will be more eﬀective than ERT for
preventing the recurrence of osteonecrosis.
Conclusions
• Recommendations for monitoring presented here are based
on an understanding and interpretation of the pathology as
well as a retrospective review of the utility of the modalities.
• Bone disease in patients with GD is prevalent, disabling, and
heterogeneous in pathology and clinical manifestations, in
both the individual and the community.
• Evidence suggests that although the pathology of BM disease
and mineral compartment are etiologically linked, separate
consideration should be given to monitoring by MRI and DXA.
Both yield useful information on the current state of disease and
the likelihood of future events such as infarction, fractures, etc.
• Therapy should address GD‐speciﬁc challenges to bone, as well
as conventional ones, and include, as for all bone diseases,
generally appropriate attention to dietary (calcium and vitamin
D) and lifestyle factors (suitable weight‐bearing exercises and
avoidance of smoking and excess alcohol consumption).
• BM disease is rapidly responsive to GD‐speciﬁc therapy.
Further work is required to understand the relation between
an improvement in the bone disease score and a change in
risk of bone events. Reduced BMD is associated with
increased fracture risk, and we need to understand whether
improvement translates into clinical eﬀect.
• Careful and agreed deﬁnitions of terminology are needed to
guide the interpretation of existing evidence and to guide
the planning of future studies.
Disclosures
DH has received honoraria for speaking and advisory boards
and research support from Genzyme Sanoﬁ and Shire. PM has
received fees from Sanoﬁ Genzyme, Shire, and Actelion for
lectures, participation at meetings, and advisory boards. NB has
received fees from Sanoﬁ Genzyme and Shire for lectures, travel
reimbursement, and participation on advisory boards. FC has
received fees from Sanoﬁ Genzyme and Shire for lectures,
participation at meetings and advisory boards, and travel
reimbursement. TMC has received fees from Sanoﬁ Genzyme,
Shire, Actelion, and Amicus for lectures, travel reimbursement,
and participation on advisory boards. OGA has received
honoraria and travel reimbursement from Sanoﬁ Genzyme.
AK has received fees from Sanoﬁ Genzyme, Shire, Amgen, and
MEDA for lectures, travel reimbursement, and participation on
advisory boards. PKM is a recipient of research grant, lecture fee
honoraria, and travel support from Sanoﬁ Genzyme and is a
consultant for Sanoﬁ Genzyme. LP has nothing to disclose. NW
has received research grant and honoraria for participating in
CME programs from Sanoﬁ Genzyme, and honoraria and travel
reimbursement for participation in medical advisory boards
from Sanoﬁ Genzyme, Shire HGT, and Pﬁzer. PD has received
honoraria for speaking and advisory boards from Sanoﬁ
Genzyme and Shire and has received research support from
Sanoﬁ Genzyme.
Acknowledgments
AK is supported by grants from the Swedish Research Council
Formas. PKM is supported by Sanoﬁ‐Genzyme Center of
◼ 14 HUGHES ET AL. Journal of Bone and Mineral Research
Excellence in Clinical Translational Research Grant and National
Institute of Arthritis and Musculoskeletal and Skin Diseases
grant R01 AR 065932065932. TMC is supported by grants from
the National Institute for Health Research, Cambridge Biome-
dical Research Centre (Metabolic Theme) and by the UK
Medical Research Council by a Stratiﬁed Medicine programme
award. Excerpta Medica, Amsterdam, the Netherlands, sup-
ported the selection, prescreening, and organization of
literature references (ﬁnancially supported by Sanoﬁ‐Genzyme
Corp./Genzyme Europe BV, Amsterdam, the Netherlands).
Preparation, moderation of working group activities, and
organization of recommendations at the meeting in
Amsterdam in 2016 were managed by an independent medical
education and communication company, Meducom BV,
Spierdijk, the Netherlands (ﬁnancially supported by Sanoﬁ‐
Genzyme Corp./Genzyme Europe BV, Amsterdam, the
Netherlands). After experts articulated the need to share this
in a manuscript, medical writing and editorial support for the
preparation of this manuscript was provided by Dr. Wilko Coers
of Meducom BV and Janet R. Davies, PhD, ELS, of Atlantic
Medical Writing, funded by Sanoﬁ‐Genzyme Corp./Genzyme
Europe BV, Amsterdam, the Netherlands.
Authors’ roles: Data analysis and interpretation: all authors.
Drafting and reviewing the manuscript: all authors. Revising the
manuscript: DH, PD, PM. Approving the ﬁnal version of the
submitted manuscript: all authors. Agreeing to be accountable
for all aspects of the work in ensuring that questions related to
the accuracy or integrity of any part of the work are
appropriately investigated and resolved: all authors. Taking
responsibility for the integrity of the data analysis: DH, PD, PM.
References
1. Hruska KS, LaMarca ME, Sidransky E Gaucher disease: molecular
biology and genotype–phenotype correlations. In: Futerman AH,
& Zimran A, editors, Gaucher disease. Volume 1. Boca Raton, FL.
CRC Press, 2007. Chapter 2, p.13.
2. Altarescu G, Hill S, Wiggs E, et al. The eﬃcacy of enzyme
replacement therapy in patients with chronic neuronopathic
Gaucher’s disease. J Pediatr. 2001;138(4):539–47.
3. Davies EH, Erikson A, Collin‐Histed T, et al. Outcome of type III
Gaucher disease on enzyme replacement therapy: Review of 55
cases. J Inherit Metab Dis. 2007;30(6):935–42.
4. Bultron G, Kacena K, Pearson D, et al. The risk of Parkinson’s
disease in type 1 Gaucher disease. J Inherit Metab Dis.
2010;33(2):167–73.
5. AHV Schapira. Glucocerebrosidase and Parkinson disease: Recent
advances. Mol Cell Neurosci. 2015;66:37–42.
6. Lee RE The pathology of Gaucher disease. In: Desnick RJ, Gatt S, &
Grabowski GA, editors, Gaucher disease, a century of delineation
and research. 9th ed. New York. Alan R. Liss, 1982) pp. 177–217.
7. McCabe ERB. Gaucher disease: current issues in diagnosis and
treatment. JAMA. 1996;275(7):548–53.
8. Cox TM. Gaucher disease: clinical proﬁle and therapeutic
developments. Biol Targets Ther. 2010;4:299–313.
9. Van Dussen L, Biegstraaten M, Hollak CE, Dijkgraaf MG. Cost‐
eﬀectiveness of enzyme replacement therapy for type 1 Gaucher
disease. Orphanet J Rare Dis. 2014;9(1):51.
10. Khan A, Hangartner T, Weinreb NJ, Taylor JS, Mistry PK. Risk factors for
fractures and avascular osteonecrosis in type 1 Gaucher disease: a
study from the International Collaborative Gaucher Group (ICGG)
Gaucher Registry. J Bone Miner Res. 2012;27(8):1839–48.
11. Marcucci G, Zimran A, Bembi B, et al. Gaucher disease and bone
manifestations. Calcif Tissue Int. 2014;95(6):477–94.
12. Masi L, Brandi ML. Gaucher disease: the role of the specialist on
metabolic bone diseases. Clin Cases Miner Bone Metab. 2015;
12(2):165–9.
13. Giuﬀrida G, Cappellini MD, Carubbi F, Di Rocco M, Iolascon G.
Management of bone disease in Gaucher disease type 1: clinical
practice. Adv Ther. 2014;31(12):1197–212.
14. Mikosch P, Hughes D. An overview on bone manifestations in
Gaucher disease. Wien Med Wochenschr. 2010;160(23‐24):609–24.
15. Wenstrup RJ, Roca‐Espiau M, Weinreb NJ, Bembi B. Skeletal
aspects of Gaucher disease: a review. Br J Radiol. 2002;75
(Suppl 1):A2–12.
16. Giraldo P, Pérez‐López J, Núñez R, et al. Patients with type 1
Gaucher disease in Spain: A cross‐sectional evaluation of health
status. Blood Cells Mol Dis. 2016;56(1):23–30.
17. Stirnemann J, Vigan M, Hamroun D, et al. The French Gaucher’s
disease registry: clinical characteristics, complications and treat-
ment of 562 patients. Orphanet J Rare Dis. 2012;7:77.
18. Kamath RS, Lukina E, Watman N, et al. Skeletal improvement in
patients with Gaucher disease type 1: a phase 2 trial of oral
eliglustat. Skeletal Radiol. 2014;43(10):1353–60.
19. De Fost, M, Aerts, et al. disease: from fundamental research to
eﬀective therapeutic interventions. Neth J Med. 2003;61(1):3–8.
20. Markuszewska‐Kuczynska A, Klimkowska M, Regenthal S, et al.
Atypical cytomorphology of Gaucher cells is frequently seen in
bone marrow smears from untreated patients with Gaucher
disease type 1. Folia Histochem Cytobiol. 2015;53(1):62–9.
21. Pastores GM, Hughes DA Gaucher disease. In: Pagon RA, Adam
MP, & Ardinger HH, editors, GeneReviews® [Internet]. Seattle, WA.
University of Washington, Seattle, 1993. [cited 2015 Jan 12].
Available from. http://www.ncbi.nlm.nih.gov/books/NBK1269/.
22. Miller SPF, Zirzow GC, Doppelt SH, Brady RO, Barton NW. Analysis
of the lipids of normal and Gaucher bone marrow. J Lab Clin Med.
1996;127:353–8.
23. Balwani M, Fuerstman L, Kornreich R, Edelmann L, Desnick RJ.
Type 1 Gaucher disease: signiﬁcant disease manifestations in
“asymptomatic” homozygotes. Arch Intern Med. 2010;170(16):
1463–9.
24. Poll LW, Cox M‐L, Godehardt E, Steinhof V, vom Dahl S. Whole
body MRI in type I Gaucher patients: evaluation of skeletal
involvement. Blood Cells Mol Dis. 2011;46(1):53–9.
25. Berger J, Lecourt S, Vanneaux V, et al. Glucocerebrosidase
deﬁciency dramatically impairs human bone marrow haemato-
poiesis in an in vitro model of Gaucher disease. Br J Haematol.
2010;150(1):93–101.
26. Scheller EL, Cawthorn WP, Burr AA, Horowitz MC, MacDougald
OA. Marrow adipose tissue: trimming the fat. Trends Endocrinol
Metab. 2016;27(6):392–403.
27. Campeau PM, Rafei M, Boivin M‐N, Sun Y, Grabowski GA, Galipeau
J. Characterization of Gaucher disease bone marrow mesench-
ymal stromal cells reveals an altered inﬂammatory secretome.
Blood. 2009;114(15):3181–90.
28. Limgala RP, Ioanou C, Plassmeyer M, et al. Time of initiating
enzyme replacement therapy aﬀects immune abnormalities and
disease severity in patients with Gaucher disease. PloS One.
2016;11(12):e0168135.
29. Sønder SU, Limgala RP, Ivanova MM, et al. Persistent immune
alterations and comorbidities in splenectomized patients with
Gaucher disease. Blood Cells Mol Dis. 2016;59:8–15.
30. Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar
MV. Clonal immunoglobulin against lysolipids in the origin of
myeloma. N Engl J Med. 2016;374(6):555–61.
31. Dekker N, van Dussen L, Hollak CEM, et al. Elevated plasma
glucosylsphingosine in Gaucher disease: relation to phenotype,
storage cell markers, and therapeutic response. Blood.
2011;118(16):e118–27.
32. De Fost M, van Noesel CJM, Aerts JMFG, Maas M, Pöll RG, Hollak
CEM. Persistent bone disease in adult type 1 Gaucher disease
despite increasing doses of enzyme replacement therapy.
Haematologica. 2008;93(7):1119–20.
Journal of Bone and Mineral Research GAUCHER DISEASE: FROM PATHOPHYSIOLOGY TO PRACTICE 15 ◼
33. Van Dussen L, Lips P, van Essen HW, Hollak CEM, Bravenboer N.
Heterogeneous pattern of bone disease in adult type 1 Gaucher
disease: clinical and pathological correlates. Blood Cells Mol Dis.
2014;53(3):118–23.
34. Lebel E, Elstein D, Peleg A, Reinus C, Zimran A, Amir G.
Histologic ﬁndings of femoral heads from patients with
Gaucher disease treated with enzyme replacement. Am J Clin
Pathol. 2013;140(1):91–6.
35. Poll LW, Koch JA, vom Dahl S, et al. Magnetic resonance imaging
of bone marrow changes in Gaucher disease during enzyme
replacement therapy: ﬁrst German long‐term results. Skeletal
Radiol. 2001;30(9):496–503.
36. Maas M, Hollak CEM, Akkerman EM, JMFG Aerts, Stoker J, Den
Heeten GJ. Quantiﬁcation of skeletal involvement in adults with
type I Gaucher’s disease: fat fraction measured by Dixon
quantitative chemical shift imaging as a valid parameter. AJR
Am J Roentgenol. 2002;179(4):961–5.
37. Poll LW, Willers R, Häussinger D, Mödder U, vom Dahl S. [MRI bone
marrow ﬁndings in 63 patients with type I Gaucher disease]. RöFo
Fortschritte Auf Dem Geb Röntgenstrahlen Nukl. 2010;182(11):
979–85.
38. Vlieger E‐JP, Maas M, Akkerman EM, Hollak CEM, Den Heeten GJ.
Vertebra disc ratio as a parameter for bone marrow involvement
and its application in Gaucher disease. J Comput Assist Tomogr.
2002;26(5):843–8.
39. Laudemann K, Moos L, Mengel KE, et al. Evaluation of bone
marrow inﬁltration in non‐neuropathic gaucher disease patients
with use of whole‐body MRI‐‐a retrospective data analysis. RöFo
Fortschritte Auf Dem Geb Röntgenstrahlen Nukl. 2015;187(12):
1093–8.
40. Gervas‐Arruga J, Cebolla JJ, de Blas I, Roca M, Pocovi M, Giraldo P.
The inﬂuence of genetic variability and proinﬂammatory status on
the development of bone disease in patients with Gaucher
disease. PloS One. 2015;10(5):e0126153.
41. Giraldo P, Alfonso P, Atutxa K, et al. Real‐world clinical experience
with long‐term miglustat maintenance therapy in type 1 Gaucher
disease: the ZAGAL project. Haematologica. 2009;94(12):1771–5.
42. Roca M, Mota J, Alfonso P, Pocoví M, Giraldo P. S‐MRI score: a
simple method for assessing bone marrow involvement in
Gaucher disease. Eur J Radiol. 2007;62(1):132–7.
43. Hermann G, Pastores GM, Abdelwahab IF, Lorberboym AM.
Gaucher disease: assessment of skeletal involvement and
therapeutic responses to enzyme replacement. Skeletal Radiol.
1997;26(12):687–96.
44. Taddei TH, Kacena KA, Yang M, et al. The underrecognized
progressive nature of N370S Gaucher disease and assessment of
cancer risk in 403 patients. Am J Hematol. 2009;84(4):208–14.
45. Komninaka V, Kolomodi D, Christoulas D, et al. Evaluation of bone
involvement in patients with Gaucher disease: a semi‐quantitative
magnetic resonance imaging method (using ROI estimation of
bone lesion) as an alternative method to semi‐quantitative
methods used so far. Eur J Haematol. 2015;95(4):342–51.
46. Weinreb NJ, Finegold DN, Feingold E, et al. Evaluation of disease
burden and response to treatment in adults with type 1 Gaucher
disease using a validated disease severity scoring system (DS3).
Orphanet J Rare Dis. 2015;10:64.
47. Di Rocco M, Giona F, Carubbi F, et al. A new severity score index
for phenotypic classiﬁcation and evaluation of responses to
treatment in type I Gaucher disease. Haematologica. 2008;93(8):
1211–8.
48. Razek AAKA, Abdalla A, Fathy A, Megahed A. Apparent diﬀusion
coeﬃcient of the vertebral bone marrow in children with
Gaucher’s disease type I and III. Skeletal Radiol. 2013;42(2):283–7.
49. Mariani G, Filocamo M, Giona F, et al. Severity of bone marrow
involvement in patients with Gaucher’s disease evaluated by
scintigraphy with 99mTc‐sestamibi. J Nucl Med. 2003;44(8):
1253–62.
50. Mariani G, Perri M., Erba PA. Bone disease scoring and manage-
ment of Gaucher disease. Clin Ther. 2009;31:S188–90.
51. Mariani G, Perri M, Minichilli F, et al. Standardization of MRI and
scintigraphic scores for assessing the severity of bone marrow
involvement in adult patients with type 1 Gaucher disease. AJR
Am J Roentgenol. 2016;206(6):1245–52.
52. Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR,
Hangartner T. Osteopenia in Gaucher disease develops early in
life: response to imiglucerase enzyme therapy in children,
adolescents and adults. Blood Cells Mol Dis. 2011;46(1):66–72.
53. De Fost M, Hollak CEM, Groener JEM, et al. Superior eﬀects of
high‐dose enzyme replacement therapy in type 1 Gaucher disease
on bone marrow involvement and chitotriosidase levels: a 2‐
center retrospective analysis. Blood. 2006;108(3):830–5.
54. Robertson PL, Maas M, Goldblatt J. Semiquantitative assessment
of skeletal response to enzyme replacement therapy for Gaucher’s
disease using the bone marrow burden score. AJR Am J
Roentgenol. 2007;188(6):1521–8.
55. Fedida B, Touraine S, Stirnemann J, Belmatoug N, Laredo J‐D,
Petrover D. Bone marrow involvement in Gaucher disease at MRI:
what long‐term evolution can we expect under enzyme replace-
ment therapy? Eur Radiol. 2015;25(10):2969–75.
56. Van Dussen L, Zimran A, Akkerman EM, et al. Taliglucerase alfa
leads to favorable bone marrow responses in patients with type I
Gaucher disease. Blood Cells Mol Dis. 2013;50(3):206–11.
57. Andersson H, Kaplan P, Kacena K, Yee J. Eight‐year clinical
outcomes of long‐term enzyme replacement therapy for 884
children with Gaucher disease type 1. Pediatrics. 2008;122(6):
1182–90.
58. Mistry PK, Lukina E, Ben Turkia H, et al. Outcomes after 18 months
of eliglustat therapy in treatment‐naïve adults with Gaucher
disease type 1: the phase 3 ENGAGE trial. Am J Hematol.
2017;92(11):1170–6.
59. Lukina E, Watman N, Dragosky M, et al. Outcomes after 8 years of
eliglustat therapy for Gaucher disease type 1: ﬁnal results from
the Phase 2 trial. Am J Hematol. 2019;94(1):29–38.
60. Cox TM, Drelichman G, Cravo R, et al. Eliglustat maintains long‐
term clinical stability in patients with Gaucher disease type 1
stabilized on enzyme therapy. Blood. 2017;129(17):2375–83.
61. Boomsma JMF, van Dussen L, Wiersma MG, et al. Spontaneous
regression of disease manifestations can occur in type 1 Gaucher
disease; results of a retrospective cohort study. Blood Cells Mol
Dis. 2010;44(3):181–7.
62. Van Dussen L, Hendriks EJ, Groener JEM, Boot RG, Hollak CEM.
Aerts JMFG. Value of plasma chitotriosidase to assess
non‐neuronopathic Gaucher disease severity and progression in
the era of enzyme replacement therapy. J Inherit Metab Dis.
2014;37(6):991–1001.
63. Zimran A, Wang N, Ogg C, Crombez E, Cohn GM, Elstein D. Seven‐
year safety and eﬃcacy with velaglucerase alfa for treatment‐
naïve adult patients with type 1 Gaucher disease. Am J Hematol.
2015;90(7):577–83.
64. Fuller M, Szer J, Stark S, Fletcher JM. Rapid, single‐phase extraction
of glucosylsphingosine from plasma: A universal screening and
monitoring tool. Clin Chim Acta. 2015;450:6–10.
65. Mirzaian M, Wisse P, Ferraz MJ, et al. Mass spectrometric
quantiﬁcation of glucosylsphingosine in plasma and urine of
type 1 Gaucher patients using an isotope standard. Blood Cells
Mol Dis. 2015;54(4):307–14.
66. Rolfs A, Giese A‐K, Grittner U, et al. Glucosylsphingosine is a highly
sensitive and speciﬁc biomarker for primary diagnostic and follow‐up
monitoring in Gaucher disease in a non‐Jewish, Caucasian cohort of
Gaucher disease patients. PloS One. 2013;8(11):e79732.
67. DeMayo RF, Haims AH, McRae MC, Yang R, Mistry PK. Correlation
of MRI‐based bone marrow burden score with genotype and
spleen status in Gaucher’s disease. AJR Am J Roentgenol.
2008;191(1):115–23.
68. Mota RMV, Mankin H. Use of plain radiography to optimize
skeletal outcomes in children with type 1 Gaucher disease in
Brazil. J Pediatr Orthop. 2007;27(3):347–50.
69. Jaramillo D, Bedoya MA, Wang D‐J, et al. Quantiﬁcation of bone
marrow involvement in treated Gaucher disease with proton
MR spectroscopy: correlation with bone marrow MRI scores
and clinical status. AJR Am J Roentgenol. 2015;204(6):
1296–302.
◼ 16 HUGHES ET AL. Journal of Bone and Mineral Research
70. Clarke LA, Hollak CEM. The clinical spectrum and pathophysiology
of skeletal complications in lysosomal storage disorders. Best
Pract Res Clin Endocrinol Metab. 2015;29(2):219–35.
71. Hughes D, Cappellini MD, Berger M, et al. Recommendations for
the management of the haematological and onco‐haematological
aspects of Gaucher disease. Br J Haematol. 2007;138(6):676–86.
72. Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth
in children with Gaucher disease after treatment with alglucerase.
J Pediatr. 1996;129(1):149–53.
73. Kauli R, Zaizov R, Lazar L, et al. Delayed growth and puberty in
patients with Gaucher disease type 1: natural history and eﬀect of
splenectomy and/or enzyme replacement therapy. Isr Med Assoc
J. 2000;2(2):158–63.
74. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc
Nephrol. 2008;3(Suppl 3):S131–9.
75. Carter A, Rajan PS, Deegan P, Cox TM, Bearcroft P. Quantifying the
Erlenmeyer ﬂask deformity. Br J Radiol. 2012;85(1015):905–9.
76. Lipschultz DH, Album MM, Stool SE, Kaufman HJ. Craniometa-
physeal dysplasia. Report of a case. Oral Surg Oral Med Oral
Pathol. 1975;40(4):464–70.
77. Percin EF, Percin S, Koptagel E, Demirel H. A case with Pyle type
metaphyseal dysplasia: clinical, radiological and histological
evaluation. Genet Couns. 2003;14(4):387–93.
78. Braun HS, Nürnberg P, Tinschert S. Metaphyseal dysplasia: a new
autosomal dominant type in a large German kindred. Am J Med
Genet. 2001;101(1):74–7.
79. Van Rijn RR, Smets AMJB. [Diagnostic image (132). A 3‐year old
boy with growth retardation]. Ned Tijdschr Geneeskd.
2003;147(13):606–7.
80. Lachman R, Crocker A, Schulman J, Strand R. Radiological ﬁndings
in Niemann‐Pick disease. Radiology. 1973;108(3):659–64.
81. Hayman AR, Cox TM. Tartrate‐resistant acid phosphatase
knockout mice. J Bone Miner Res. 2003;18(10):1905–7.
82. Hayman AR, Cox TM. Tartrate‐resistant acid phosphatase: a
potential target for therapeutic gold. Cell Biochem Funct.
2004;22(5):275–80.
83. Hayman AR, Jones SJ, Boyde A, et al. Mice lacking tartrate‐
resistant acid phosphatase (Acp 5) have disrupted endochondral
ossiﬁcation and mild osteopetrosis. Development. 1996;122(10):
3151–62.
84. Deegan PB, Pavlova E, Tindall J, et al. Osseous manifestations of
adult Gaucher disease in the era of enzyme replacement therapy.
Medicine (Baltimore). 2011;90(1):52–60.
85. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling
and remodeling. Arch Biochem Biophys. 2008;473(2): 139–46.
86. Kramer I, Halleux C, Keller H, et al. Osteocyte Wnt/beta‐catenin
signaling is required for normal bone homeostasis. Mol Cell Biol.
2010;30(12):3071–85.
87. Mistry PK, Liu J, Yang M, et al. Glucocerebrosidase gene‐deﬁcient
mouse recapitulates Gaucher disease displaying cellular and
molecular dysregulation beyond the macrophage. Proc Natl Acad
Sci USA. 2010;107(45):19473–8.
88. Reed M, Baker RJ, Mehta AB, Hughes DA. Enhanced diﬀerentiation
of osteoclasts from mononuclear precursors in patients with
Gaucher disease. Blood Cells Mol Dis. 2013;51(3):185–94.
89. Lecourt S, Mouly E, Freida D, et al. A prospective study of bone
marrow hematopoietic and mesenchymal stem cells in type 1
Gaucher disease patients. PloS One. 2013;8(7):e69293.
90. Drugan C, Jebeleanu G, Grigorescu‐Sido P, Caillaud C, Craciun AM.
Biochemical markers of bone turnover as tools in the evaluation
of skeletal involvement in patients with type 1 Gaucher disease.
Blood Cells Mol Dis. 2002;28(1):13–20.
91. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic
bone resorption leads to osteopetrosis in cathepsin‐K‐deﬁcient
mice. Proc Natl Acad Sci USA. 1998;95(23):13453–8.
92. Moran MT, Schoﬁeld JP, Hayman AR, Shi GP, Young E, Cox TM.
Pathologic gene expression in Gaucher disease: up‐regulation of
cysteine proteinases including osteoclastic cathepsin K. Blood.
2000;96(5):1969–78.
93. Ciana G, Deroma L, Franzil AM, Dardis A, Bembi B. Long‐term bone
mineral density response to enzyme replacement therapy in a
retrospective pediatric cohort of Gaucher patients. J Inherit Metab
Dis. 2012;35(6):1101–6.
94. Mikosch P, Reed M, Stettner H, Baker R, Mehta AB, Hughes DA.
Patients with Gaucher disease living in England show a high
prevalence of vitamin D insuﬃciency with correlation to
osteodensitometry. Mol Genet Metab. 2009;96(3):113–20.
95. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density
in type 1 Gaucher disease. J Bone Miner Res. 1996;11(11):1801–7.
96. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive
summary of the 2013 International Society for Clinical Densito-
metry Position Development Conference on bone densitometry. J
Clin Densitom. 2013;16(4):455–66.
97. Marshall D, Johnell O, Wedel H. Meta‐analysis of how well
measures of bone mineral density predict occurrence of
osteoporotic fractures. BMJ. 1996;312(7041):1254–9.
98. Kanis JA. Assessment of fracture risk and its application to
screening for postmenopausal osteoporosis: synopsis of a WHO
report. WHO Study Group. Osteoporos Int. 1994;4(6):368–81.
99. Bianchi ML, Baim S, Bishop NJ, et al. Oﬃcial positions of the
International Society for Clinical Densitometry (ISCD) on DXA
evaluation in children and adolescents. Pediatr Nephrol.
2010;25(1):37–47.
100. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry:
demographics and disease characteristics of 1698 patients with
Gaucher disease. Arch Intern Med. 2000;160(18):2835–43.
101. Javier R‐M, Hachulla E, Rose C, et al. Vertebral fractures in Gaucher
disease type I: data from the French “Observatoire” on Gaucher
disease (FROG). Osteoporos Int. 2011;22(4):1255–61.
102. Stone KL, Seeley DG, Lui L‐Y, et al. BMD at multiple sites and
risk of fracture of multiple types: long‐term results from the
Study of Osteoporotic Fractures. J Bone Miner Res. 2003;
18(11):1947–54.
103. Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and
demographic characteristics of nonneuronopathic Gaucher dis-
ease in 887 children at diagnosis. Arch Pediatr Adolesc Med.
2006;160(6):603–8.
104. Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease:
alendronate disodium improves bone mineral density in adults
receiving enzyme therapy. Blood. 2004;104(5):1253–7.
105. Charrow J, Scott CR. Long‐term treatment outcomes in Gaucher
disease. Am J Hematol. 2015;90(Suppl 1):S19–24.
106. Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ.
Bone complications in children with Gaucher disease. Br J Radiol.
2002;75(Suppl 1):A37–44.
107. Zimran A, Morris E, Mengel E, et al. The female Gaucher patient:
the impact of enzyme replacement therapy around key repro-
ductive events (menstruation, pregnancy and menopause). Blood
Cells Mol Dis. 2009;43(3):264–88.
108. Giraldo P, Solano V, Pérez‐Calvo J‐I, Giralt M, Rubio‐Félix D,
Spanish Group on Gaucher disease. Quality of life related to
type 1 Gaucher disease: Spanish experience. Qual Life Res.
2005;14(2):453–62.
109. Bell RS, Mankin HJ, Doppelt SH. Osteomyelitis in Gaucher disease.
J Bone Joint Surg Am. 1986;68(9):1380–8.
110. Baris HN, Cohen IJ, Mistry PK. Gaucher disease: the metabolic
defect, pathophysiology, phenotypes and natural history. Pediatr
Endocrinol Rev. 2014;12(Suppl 1):72–81.
111. Mikosch P, Kohlfürst S, Gallowitsch HJ, et al. Is there a role for
scintigraphic imaging of bone manifestations in Gaucher disease?
A review of the literature. Nucl Med. 2008;47(6):239–47.
112. Lacerda L, Arosa FA, Lacerda R, et al. T cell numbers relate to
bone involvement in Gaucher disease. Blood Cells Mol Dis.
1999;25(2):130–8.
113. Fairley C, Zimran A, Phillips M, et al. Phenotypic heterogeneity of
N370S homozygotes with type I Gaucher disease: an analysis of
798 patients from the ICGG Gaucher Registry. J Inherit Metab Dis.
2008;31(6):738–44.
Journal of Bone and Mineral Research GAUCHER DISEASE: FROM PATHOPHYSIOLOGY TO PRACTICE 17 ◼
114. Shitrit D, Rudensky B, Zimran A, Elstein D. D‐dimer assay in
Gaucher disease: correlation with severity of bone and lung
involvement. Am J Hematol. 2003;73(4):236–9.
115. Sherif EM, Tantawy AAG, Adly AAM, Kader HA, Ismail EAR. D‐
dimer assay in Egyptian patients with Gaucher disease:
correlation with bone and lung involvement. Blood Coagul
Fibrinolysis. 2011;22(3):176–84.
116. Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH. Coagulation
abnormalities in type 1 Gaucher disease are due to low‐grade
activation and can be partly restored by enzyme supplementation
therapy. Br J Haematol. 1997;96(3):470–6.
117. Poll LW, vom Dahl S, Koch JA, et al. [Gaucher disease: MR
evaluation of bone marrow features during treatment with
enzyme replacement]. RöFo Fortschritte Auf Dem Geb Röntgen-
strahlen Nukl. 2001;173(10):931–7.
118. Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ. Timing
of initiation of enzyme replacement therapy after diagnosis of
type 1 Gaucher disease: eﬀect on incidence of avascular necrosis.
Br J Haematol. 2009;147(4):561–70.
119. Bax BE, Richﬁeld L, Bain MD, Mehta AB, Chalmers RA, Rampling
MW. Haemorheology in Gaucher disease. Eur J Haematol.
2005;75(3):252–8.
120. Franco M, Collec E, Connes P, et al. Abnormal properties of red
blood cells suggest a role in the pathophysiology of Gaucher
disease. Blood. 2013;121(3):546–55.
121. Zahran AM, Elsayh KI, El‐Deek SEM, El‐Baz MAH. Oxidative stress,
trace elements, and circulating microparticles in patients with
Gaucher disease before and after enzyme replacement therapy.
Clin Appl Thromb. 2015;21(1):58–65.
122. Mistry PK, Belmatoug N, vom Dahl S, Giugliani R. Understanding
the natural history of Gaucher disease. Am J Hematol.
2015;90(Suppl 1):S6–11.
123. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of
diagnostic delays in type 1 Gaucher disease: the need for greater
awareness among hematologists‐oncologists and an opportunity
for early diagnosis and intervention. Am J Hematol. 2007;
82(8):697–701.
◼ 18 HUGHES ET AL. Journal of Bone and Mineral Research
